| abstract |
The present disclosure relates generally to highly concentrated macrolide solutions for aerosol administration, and related methods of producing and administering the same. In one aspect, provided herein is a receptacle containing a highly concentrated solution of a macrolide compound such as tacrolimus, where the solution exhibits long-term stability in a pMDI canister and achieves high respirable fractions when actuated, among other features. In yet another aspect, provided is a composition suitable for aerosol administration comprising tacrolimus dissolved in an ethanol-liquified propeliant mixture, characterized by a tacrolimus concentration of greater than 0.15 weight percent (w/w) and comprising no more than about 10 weight percent (w/w) ethanol. |